Histamine release from basophils in cystic fibrosis
- PMID: 2473860
- PMCID: PMC1541905
Histamine release from basophils in cystic fibrosis
Abstract
We determined the histamine release from basophils in patients suffering from cystic fibrosis (CF) (median 17.2 years of age) and compared the data with an age-matched group of healthy donors. No significant differences in the basophil counts were determined between the CF and control groups. However, the absolute histamine content per basophil was elevated in the CF group (2.6 +/- 0.4 pg/basophil versus 1.4 +/- 0.2, mean +/- s.e.m., n = 15/10, P less than 0.004). Stimulation of basophils with the Ca ionophore (7.5 microM) and anti-IgE (10(-2) of a stock preparation) leads to a significantly higher release of histamine per basophil in CF patients as compared to healthy donors (Ca ionophore: 1.6 +/- 0.2 versus 0.9 +/- 0.2, mean +/- s.e.m., P less than 0.008; anti-IgE: 0.45 +/- 0.007 versus 0.28 +/- 0.04, P less than 0.02). These data indicate that basophils in CF may have a greater potential to release mediators although their releasability, expressed as the percentage of histamine release of the total histamine content, does not differ significantly compared to the healthy donors (62.1 +/- 8.3% versus 60.2 +/- 13%, mean +/- s.e.m.). Within the 14-day period of intravenous antibiotic treatment of the pulmonary infection (in 14 out of 15 cases P. aeruginosa was isolated from sputa samples) histamine release per basophil and total histamine content decreased to normal levels (day 1 2.6 +/- 0.3 versus 1.8 +/- 0.3, P less than 0.05). This decline was accompanied by an improvement of the clinical condition of the patient and reduction of P. aeruginosa isolates in sputa (n = 8). In contrast, in three patients with sustained P. aeruginosa colonization of the upper airways and impaired lung function histamine levels remained elevated. Our data demonstrate that the histamine content of basophils, as well as the release of histamine, is increased in patients with cystic fibrosis and correlates with the clinical signs of the chronic infection.
Similar articles
-
[LTB4-metabolism and histamine liberation by granulocytes in the disease pattern of cystic fibrosis (CF)].Pneumologie. 1991 Nov;45(11):913-23. Pneumologie. 1991. PMID: 1722312 Review. German.
-
Pseudomonas aeruginosa allergy in cystic fibrosis. Involvement of histamine release in the pathogenesis of lung tissue damage.Allergy. 1980 Jan;35(1):23-9. doi: 10.1111/j.1398-9995.1980.tb01713.x. Allergy. 1980. PMID: 6154430
-
Basophil releasability in the newborn: factors limiting immunoglobulin E-mediated histamine release.Pediatrics. 1982 Feb;69(2):188-92. Pediatrics. 1982. PMID: 6173838
-
Human basophil releasability. III. Genetic control of human basophil releasability.J Immunol. 1986 Dec 1;137(11):3588-92. J Immunol. 1986. PMID: 2431036
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
Cited by
-
Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes.Infect Immun. 1996 Aug;64(8):3252-8. doi: 10.1128/iai.64.8.3252-3258.1996. Infect Immun. 1996. PMID: 8757861 Free PMC article.
-
Immunomodulation in Cystic Fibrosis: Why and How?Int J Mol Sci. 2020 May 8;21(9):3331. doi: 10.3390/ijms21093331. Int J Mol Sci. 2020. PMID: 32397175 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical